Accelerated Cancer Drugs Face Delayed Reckonings

Cancer drugs granted accelerated approval but offering limited benefit often take the longest to complete confirmatory trials and secure full approval or face withdrawal. Yet, once negative evidence emerges, clinicians and insurers tend to abandon those therapies quickly even when off-label use remains possible—a sign of real-world course correction, researchers say, but one that responds too slowly to ineffective or underperforming drugs.